Koers CV Sciences, Inc. Other OTC
Aandelen
CVSI
US1266541028
Farmaceutische producten
Omzet 2022 | 16,2 mln. 15,06 mln. | Omzet 2023 | 16 mln. 14,87 mln. | Marktkapitalisatie | 5,47 mln. 5,08 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -9 mln. -8,36 mln. | Nettowinst (verlies) 2023 | 3 mln. 2,79 mln. | EV/omzet 2022 | 0,36 x |
Nettoschuld 2022 | 917K 852K | Nettoliquiditeiten 2023 | 875K 813K | EV/omzet 2023 | 0,29 x |
K/w-verhouding 2022 |
-0,44
x | K/w-verhouding 2023 |
1,77
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99,98% |
Recentste transcriptie over CV Sciences, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joseph Dowling
CEO | Chief Executive Officer | 66 | 16-06-14 |
Joerg Grasser
DFI | Director of Finance/CFO | 49 | 26-12-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Joseph Dowling
CEO | Chief Executive Officer | 66 | 16-06-14 |
Jamie Corroon
BRD | Director/Board Member | 54 | 21-07-22 |
William McCorkle
BRD | Director/Board Member | 56 | 21-10-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,08% | 662 mld. | |
+21,85% | 546 mld. | |
-4,77% | 359 mld. | |
+16,97% | 323 mld. | |
+5,69% | 290 mld. | |
+13,68% | 234 mld. | |
+3,65% | 198 mld. | |
-11,12% | 194 mld. | |
-3,40% | 157 mld. |